Progession as exemplified by human astrocytic tumors

Seminars in Cancer Biology

Volumn 9, Issue 4, 1999, Pages 267-276

  Collins, V P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cell cycle; Gliomas; Oncogenes; Supressor genes

Indexed keywords

PROTEIN P53;

ALLELE; ASTROCYTOMA; CANCER GENETICS; CARCINOGENESIS; CELL CYCLE S PHASE; GENE DELETION; GENE MUTATION; GENOME; GLIOBLASTOMA; HUMAN; PHENOTYPE; REVIEW; BRAIN TUMOR; CELL CYCLE; CLASSIFICATION; DISEASE COURSE; GENETICS; MUTATION; ONCOGENE; PATHOLOGY; PHYSIOLOGY;

ASTROCYTOMA; BRAIN NEOPLASMS; CELL CYCLE; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; MUTATION; ONCOGENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032587217     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1999.0132     Document Type: Article

References (82)

1. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. 2nd ed. World Health Organization. International histological classification of tumors. 1993;Springer-Verlag, New York:
2. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg. 71:1989;487-493.
3. James CD, Carlbom E, Dumanski JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 48:1988;5546-5551.
4. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Path. 3:1993;19-26.
5. Reifenberger J, Ring GU, Gies U, et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol. 55:1996;822-831.
6. McCormack BM, Miller DC, Budzilovich GN, et al. Treatment and survival of low-grade astrocytoma in adults - 1977-1988. Neurosurgery. 31:1992;636.
7. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Rad Oncol, Biol, Phys. 26:1993;239-244.
8. Weber RG, Sabel M, Reifenberger J, et al. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene. 13:1996;983-994.
9. Scherer HJ. Cerebral astrocytomas and their derivatives. Am J Cancer. 40:1940;159-198.
10. Bigner SH, Mark J, Mahaley JMS, et al. Patterns of the early gross chromosomal changes in malignant human gliomas. Hereditas. 101:1984;103-113.
11. Bigner SH, Mark J, Bigner DD. Cytogenetics of human brain tumors. Cancer Genet Cytogen. 47:1990;141-154.
12. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:1984;418-425.
13. James CD, Carlbom E, Nordenskjold M, et al. Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci USA. 86:1989;2858-2862.
14. Fujimoto M, Fults DW, Thomas GA, et al. Loss of heterozygosity on chromosome 10 in human glioblastoma multiforme. Genomics. 4:1989;210-214.
15. Giannini C, Scheithauer BW. Classification and grading of low-grade astrocytic tumors in children. Brain Pathol. 7:1997;785-798.
16. Agamanolis DP, Malone JM. Chromosomal abnormalities in 47 pediatric brain tumors. Cancer Genet Cytogene. 81:1995;125-134.
17. Bigner SH, McLendon RE, Fuchs H, et al. Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogen. 97:1997;125-134.
18. Jenkins RB, Kimmel DW, Moertel CA, et al. A cytogenetic study of 53 human gliomas. Cancer Genet Cytogene. 39:1989;253-279.
19. James CD, He J, Carlbom E, et al. Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosome Cancer. 2:1990;94-102.
20. Ransom DT, Ritland SR, Kimmel DW, et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosom Cancer. 5:1992;348-356.
21. White FV, Anthony DC, Yunis EJ, et al. non-random chromosomal gains in pilocytic astrocytomas of childhood. Hum Pathol. 26:1995;979-986.
22. Zattara-Cannoni H, Gambarelli D, Lena G, et al. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet Cytogen. 104:1998;157-160.
23. Patt S, Gries H, Giraldo M, et al. p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum Pathol. 27:1996;586-589.
24. von Deimling A, Louis DN, Menon AG et al. Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathol (Berl). 86:1993;81-85.
25. Platten M, Giordano MJ, Dirven CM, et al. Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol. 149:1996;621-627.
26. Kimmel DW, O'Fallon JR, Scheithauer BW, et al. Prognostic value of cytogenetic analysis in human cerebral astrocytomas. Ann Neurol. 31:1992;534-542.
27. el-Azouzi M, Chung RY, Farmer GE, et al. Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas. Proc Natl Acad Sci USA. 86:1989;7186-7190.
28. Fults D, Pedone CA, Thomas GA, et al. Allelotype of human malignant astrocytoma. Cancer Res. 50:1990;5784-5789.
29. Fults D, Brockmeyer D, Tullous MW, et al. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res. 52:1992;674-679.
30. Wu JK, Darras BT. Loss of heterozygosity on the short arm of chromosome 17 in human astrocytomas. Neurol Res. 14:1992;39-44.
31. von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res. 52:1992;2987-2990.
32. Ohgaki H, Eibl RH, Schwab M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Molec Carcinogen. 8:1993;74-80.
33. Rasheed, BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res. 54:1994;1324-1330.
34. Kraus JA, Bolln C, Wolf HK, et al. TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosom Cancer. 10:1994;143-149.
35. Liang BC, Ross DA, Greenberg HS, et al. Evidence of allelic imbalance of chromosome 6 in human astrocytomas [published erratum appears in Neurology 1994 44(6):1190]. Neurology. 44:1994;533-536.
36. Ichimura K, Schmidt EE, Goike HM, et al. Human glioblastomas with no alterations of the CDKN2A (p16INK4a, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene. 13:1996;1065-1072.
37. Ichimura K, Schmidt EE, Miyakawa A, et al. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosome Cancer. 1998.
38. Hoang-Xuan K, Merel P, Vega F, et al. Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas. Int J Cancer. 60:1995;478-481.
39. Schmidt EE, Ichimura K, Messerle KR, et al. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer. 75:1997;2-8.
40. Reifenberger G, Reifenberger J, Ichimura K, et al. Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Cancer Res. 55:1995;731-734.
41. Ekstrand AJ, James CD, Cavenee WK, et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:1991;2164-2172.
42. Ransom, DT, Ritland SR, Moertel CA, et al. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosom Cancer. 5:1992;357-374.
43. Schröck E, Thiel G, Lozanova T, et al. Comparative genomic hybridization of human malignant gliomas reveals multiple amplification sites and non-random chromosomal gains and losses. Am J Pathol. 144:1994;1203-1218.
44. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 95:1998;5-8.
45. Reifenberger G, Reifenberger J, Ichimura K, et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res. 54:1994;4299-4303.
46. Reifenberger G, Ichimura K, Reifenberger J, et al. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res. 56:1996;5141-5145.
47. Rey JA, Bello MJ, de Campos JM, et al. Chromosomal patterns in human malignant astrocytomas. Cancer Genet Cytogene. 29:1987;201-221.
48. Bigner SH, Mark J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48:1988;405-411.
49. Bigner SH, Burger PC, Wong AJ, et al. Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol. 47:1988;191-205.
50. Bigner SH, Mark J, Bigner DD. Cytogenetics of human brain tumors. [Review] [78 refs]. Cancer Genet Cytogene. 47:1990;141-154.
51. Mohapatra G, Kim DH, Feuerstein BG. Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosome Cancer. 13:1995;86-93.
52. Muleris M, Almeida A, Dutrillaux AM, et al. Oncogene amplification in human gliomas: a molecular cytogenetic analysis. Oncogene. 9:1994;2717-2722.
53. Schmidt EE, Ichimura K, Reifenberger G, et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:1994;6321-6324.
54. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1:1995;686-692.
55. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525-4530.
56. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55:1995;4531-4535.
57. Costello JF, Berger MS, Huang HS, et al. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 56:1996;2405-2410.
58. Fueyo J, Gomez-Manzano C, Bruner JM, et al. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene. 13:1996;1615-1619.
59. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 313:1985;144-147.
60. Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA. 87:1990;8602-8606.
61. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA. 89:1992;2965-2969.
62. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA. 87:1990;4207-4211.
63. Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene. 9:1994;2313-2320.
64. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 91:1994;7727-7731.
65. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA. 89:1992;4309-4313.
66. Fults D, Pedone C. Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme. Genes Chromosome Cancer. 7:1993;173-177.
67. Karlbom, AE, James CD, Boethius J, et al. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet. 92:1993;169-174.
68. Rasheed, BK, Fuller GN, Friedman AH, et al. Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosome Cancer. 5:1992;75-82.
69. Rasheed BK, McLendon RE, Friedman HS, et al. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene. 10:1995;2243-2246.
70. Kimmelman AC, Ross DA, Liang BC. Loss of heterozygosity of chromosome 10p in human gliomas. Genomics. 34:1996;250-254.
71. Albarosa, R, Colombo BM, Roz L, et al. Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Gene. 58:1996;1260-1267.
72. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [see comments]. Science. 275:1997;1943-1947.
73. Steck, PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Gene. 15:1997;356-362.
74. Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA. 94:1997;9052-9057.
75. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase a ctivity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA. 95:1998;13513-13518.
76. Rasheed BKA, Stenzel TT, McLendon RE, et al. Pten Gene Mutations Are Seen In High-Grade But Not In Low-Grade Gliomas. Cancer Res. 57:1997;4187-4190.
77. Wang SI, Puc J, Li J, et al. Somatic Mutations Of Pten In Glioblastoma Multiforme. Cancer Res. 57:1997;4183-4186.
78. Wang JY, Knudsen ES, Welch PJ. The retinoblastoma tumor suppressor protein. Adv Cancer Res. 64:1994;25-85.
79. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
80. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
81. Roth J, Dobbelstein M, Freedman DA, et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. Embo J. 17:1998;554-564.
82. Weber RG, Sommer C, Albert FK, et al. Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. Lab Invest. 74:1996;108-119.